Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Diagnos ( (TSE:ADK) ) has provided an announcement.
Diagnos Inc. has announced an amendment to the terms of its unsecured convertible debentures, extending the maturity date from March 1, 2025, to March 1, 2026, and increasing the interest rate from 8% to 10% for the extended period. This amendment is subject to acceptance by the TSX Venture Exchange and aims to adjust financial terms to better align with market conditions, potentially impacting investor relations and financial strategy.
More about Diagnos
DIAGNOS is a publicly-traded Canadian corporation specializing in the development of software tools for the early detection of critical health issues using Artificial Intelligence.
YTD Price Performance: 13.33%
Average Trading Volume: 220,964
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$34.37M
See more data about ADK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue